DK0493446T3 - Behandling af autoimmunsygdom. - Google Patents

Behandling af autoimmunsygdom.

Info

Publication number
DK0493446T3
DK0493446T3 DK90913991.7T DK90913991T DK0493446T3 DK 0493446 T3 DK0493446 T3 DK 0493446T3 DK 90913991 T DK90913991 T DK 90913991T DK 0493446 T3 DK0493446 T3 DK 0493446T3
Authority
DK
Denmark
Prior art keywords
segment
immunoglobulin
migis
suppression
treatment
Prior art date
Application number
DK90913991.7T
Other languages
Danish (da)
English (en)
Inventor
Tse Wen Chang
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Application granted granted Critical
Publication of DK0493446T3 publication Critical patent/DK0493446T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90913991.7T 1989-09-15 1990-09-14 Behandling af autoimmunsygdom. DK0493446T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40812389A 1989-09-15 1989-09-15

Publications (1)

Publication Number Publication Date
DK0493446T3 true DK0493446T3 (da) 1997-08-11

Family

ID=23614953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90913991.7T DK0493446T3 (da) 1989-09-15 1990-09-14 Behandling af autoimmunsygdom.

Country Status (9)

Country Link
EP (1) EP0493446B1 (de)
JP (1) JP2852705B2 (de)
AT (1) ATE148348T1 (de)
AU (1) AU639719B2 (de)
CA (1) CA2065414C (de)
DE (1) DE69029858T2 (de)
DK (1) DK0493446T3 (de)
ES (1) ES2100892T3 (de)
WO (1) WO1991004055A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
CA2130173A1 (en) * 1992-03-17 1993-09-30 Norman Hardman Genetically engineered antibodies
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE10127712A1 (de) * 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
AU2009286956B2 (en) * 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
CN102482351B (zh) 2009-02-25 2015-03-18 中央研究院 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
AU2013234046B2 (en) * 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
WO2013158274A1 (en) 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
AU2014357450B2 (en) * 2013-12-03 2019-10-03 Welt Bio-Molecular Pharmaceutical, Llc Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
JP6316966B2 (ja) * 2013-12-05 2018-04-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ ｍＩｇＡ−Ｂリンパ球の溶解及びＩｇＡ生産の減少が可能な抗ヒトｍＩｇＡ抗体
JP7286665B2 (ja) 2017-10-31 2023-06-05 ワンネス バイオテック カンパニー リミティド ＩｇＥ介在アレルギー性疾患の治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4545986A (en) * 1982-06-22 1985-10-08 Research Corporation Timothy grass antigen specific anti-idiotypic antibodies
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD230879B1 (de) * 1983-09-08 1987-06-17 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper fuer human-igm
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
JPS6468398A (en) * 1987-09-08 1989-03-14 Agency Ind Science Techn Monoclonal anti-idiotype antibody and hybridoma and use thereof
EP0617127A1 (de) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigene Epitope auf B-Zell-gebundene IgE Immunglobulinen

Also Published As

Publication number Publication date
DE69029858D1 (de) 1997-03-13
JP2852705B2 (ja) 1999-02-03
AU639719B2 (en) 1993-08-05
AU6437690A (en) 1991-04-18
WO1991004055A1 (en) 1991-04-04
JPH05503687A (ja) 1993-06-17
EP0493446A1 (de) 1992-07-08
ATE148348T1 (de) 1997-02-15
CA2065414C (en) 2007-05-15
EP0493446A4 (en) 1993-03-31
ES2100892T3 (es) 1997-07-01
DE69029858T2 (de) 1997-08-21
CA2065414A1 (en) 1991-03-16
EP0493446B1 (de) 1997-01-29

Similar Documents

Publication Publication Date Title
DK0493446T3 (da) Behandling af autoimmunsygdom.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
DE69429095D1 (de) Humanisierte antikoerper
ATE222928T1 (de) Humanisierte antikörper gegen cd38
ATE419276T2 (de) Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d
KR910002897A (ko) 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DK0703922T3 (da) Fremgangsmåde til fremstilling af immunoglobulin G koncentrat
PT91170A (pt) Processo de preparacao de um preparado de imunoglobulina policlonal com elevado teor de igm
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
DE60014239D1 (de) Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität
DE69125485T2 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
FI20040696A (fi) Immunoglobuliini-isotyyppiä vastaan suunnatut uudelleenmuotoillut monoklonaaliset vasta-aineet
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
ATE401912T1 (de) Methoden der zubereitung von immunglobulin und dessen verwendungen
ATE122100T1 (de) Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen.
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
DK0656906T3 (da) Endothelcellemolekyle, der medierer lymfocytbinding i mennesket
Kresina et al. An immunoregulatory human monoclonal antibody in Schistosomiasis japonica
Wines et al. The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues
Sato et al. Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC).